Harvest Fund Management Co., LTD Bei Gene, Ltd. Transaction History

Harvest Fund Management Co., LTD

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$249.6 - $403.14 $6.18 Million - $9.98 Million	-24,745 Closed	0 $0
Q1 2021 May 13, 2021	SELL	$260.64 - $382.12 $1.32 Million - $1.94 Million	-5,083 Reduced 17.04%	24,745 $8.61 Million
Q4 2020 Feb 10, 2021	BUY	$221.31 - $316.61 $244,547 - $349,854	1,105 Added 3.85%	29,828 $7.71 Million
Q3 2020 Nov 04, 2020	BUY	$189.18 - $286.44 $5.43 Million - $8.23 Million	28,723 New	28,723 $8.79 Million
Q1 2019 May 14, 2019	SELL	$122.82 - $151.83 $12.3 Million - $15.2 Million	-100,000 Closed	0 $0
Q2 2018 Aug 03, 2018	BUY	$152.5 - $216.77 $13.7 Million - $19.5 Million	90,000 Added 900.0%	100,000 $15.4 Million
Q1 2018 May 08, 2018	BUY	$97.41 - $177.22 $974,100 - $1.77 Million	10,000 New	10,000 $1.68 Million

252

45.3M

292K

119K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $18.7B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of Harvest Fund Management Co., LTD, based on Form 13F filings with the SEC.

Stay updated on Harvest Fund Management Co., LTD with notifications on news.